Carbidopa and Levodopa
Total Payments
$391,951
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $80.00 | 1 | 0 |
| 2021 | $391,871 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $391,951 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CBLV-TBR-1002 | Mylan Pharmaceuticals Inc. | $391,951 | 0 |
Top Doctors Receiving Payments for Carbidopa and Levodopa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $391,951 | 7 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $391,951
Product Information
- Type Drug
- Total Payments $391,951
- Total Doctors 0
- Transactions 7
About Carbidopa and Levodopa
Carbidopa and Levodopa is a drug associated with $391,951 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2021 to 2022. In 2022, $80.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for Carbidopa and Levodopa is "Unspecified" ($391,951, 100.0% of total).
Carbidopa and Levodopa is associated with 1 research study, including "CBLV-TBR-1002" ($391,951).